Drug intelligence / Profile preview

EKZ-317

Development stage: Preclinical
Lead developer: Eikonizo Therapeutics
Modality: Small Molecules

Overview

EKZ-317 is a potent and selective small molecule inhibitor of histone deacetylase 6 (HDAC6) developed by Eikonizo Therapeutics. It is designed for high blood-brain barrier penetration and target occupancy, making it suitable for treating central nervous system disorders. Preclinically, EKZ-317 has been used to validate HDAC6-targeted PET imaging technology and has shown potential in models of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease. Although it exhibits favorable pharmacological properties, Eikonizo's lead clinical development program currently focuses on EKZ-102, with EKZ-317 serving as a key research and discovery compound in their pipeline.

Targets

HDAC6 (Histone deacetylase 6)

Beyond the preview

Go deeper on EKZ-317.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EKZ-317.

Explore the full profile